Form 4: Co-Diagnostics CFO Reports RSU Vesting & Tax-Related Stock Sale

Co-Diagnostics, Inc. Chief Financial Officer Brian Lee Brown reported the vesting of restricted stock units and a subsequent mandatory sale of shares to cover tax obligations.

Summary

• Chief Financial Officer Brian Lee Brown acquired 134,167 shares of Co-Diagnostics, Inc. common stock through the vesting of Restricted Stock Units (RSUs) on November 23, 2025.
• Concurrently, 40,723 shares were disposed of at a price of $0.35 per share to cover tax withholding obligations in connection with the RSU vesting.
• The sale of shares for tax withholding was mandated by the Issuer's equity incentive plans and does not represent a discretionary trade by the Reporting Person.
• Following these transactions, Brian Lee Brown beneficially owns 599,355 shares of common stock and 337,500 Restricted Stock Units.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction related to executive compensation and tax obligations, not indicative of positive or negative company performance or strategic shifts.

Positives

• Chief Financial Officer Brian Lee Brown continues to hold a significant number of shares (599,355) and Restricted Stock Units (337,500), indicating continued alignment with shareholder interests.
• The vesting of RSUs is a standard component of executive compensation, reflecting the company's long-term incentive plan.

Negatives

• A portion of shares (40,723) was sold, although this was a non-discretionary 'sell to cover' for tax purposes rather than a voluntary disposition.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction related to equity compensation.

Industry Context

This filing is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or the competitive landscape. It reflects standard equity incentive plan operations within the biotechnology or diagnostics sector.

Comparison to Industry Standards

• This filing reports a routine insider transaction (RSU vesting and tax-related sale) which is a common practice in executive compensation across various industries.
• No specific company performance metrics or projects are detailed in this Form 4 to allow for a direct comparison to industry-specific benchmarks or competitor results.

Related Party Transactions

• The vesting of Restricted Stock Units (RSUs) awarded to the Chief Financial Officer under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan constitutes a related party dealing as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: The CFO's continued significant ownership (599,355 shares and 337,500 RSUs) aligns his interests with shareholders. The 'sell to cover' is a standard, non-discretionary event and does not signal a lack of confidence.
• Employees: The filing highlights the company's use of equity incentive plans (2015 Long Term Incentive Plan) as part of its compensation strategy.

Next Steps

• Future vesting events for the remaining Restricted Stock Units will occur in 6-month installments as per the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the vesting of Restricted Stock Units and a mandatory 'sell to cover' for tax purposes. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The CFO's continued substantial equity holdings suggest ongoing alignment with shareholder interests. Investors should maintain their current position based on broader company fundamentals rather than this specific filing.

Keywords

Co-Diagnostics, CODX, Form 4, Insider Transaction, Restricted Stock Units, RSU, CFO, Brian Lee Brown, Stock Vesting, Sell to Cover, Equity Compensation